How Many Units Is 2.5 mg of Semaglutide? Complete Conversion Chart for Compounded Dosing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At 10 mg/mL (the most common compounded concentration), 2.5 mg of semaglutide equals 25 units on a U-100 insulin syringe, or 0.25 mL
• The unit count changes with concentration: 50 units at 5 mg/mL, 12.5 units at 20 mg/mL, or 10 units at 25 mg/mL
• "Units" is technically incorrect terminology for semaglutide (it's not insulin), but pharmacies use it because patients inject with U-100 insulin syringes
• The single most common dosing error is switching pharmacies without recalculating units for the new concentration

Direct answer (40-60 words)

For compounded semaglutide at 10 mg/mL concentration, 2.5 mg equals 25 units on a U-100 insulin syringe. At 5 mg/mL it's 50 units. At 20 mg/mL it's 12.5 units. The answer depends entirely on your vial's concentration, which must be printed on the label or pharmacy instructions.

Table of contents

1. Why the unit count depends on concentration
2. Complete conversion chart for all common semaglutide concentrations
3. How to locate your vial's concentration
4. The Three-Check Method for drawing 2.5 mg accurately
5. What most articles get wrong about semaglutide unit conversions
6. Common dosing errors and the pattern we see in refill data
7. When higher concentrations make sense (and when they don't)
8. Reconstituted semaglutide: calculating concentration after mixing
9. Storage requirements and visual inspection before each dose
10. When to contact your provider about dosing questions
11. FAQ
12. Sources

Why the unit count depends on concentration

A "unit" has no universal meaning for semaglutide. The term comes from insulin dosing, where one unit represents a standardized measure of biological activity. Semaglutide is a GLP-1 receptor agonist peptide, not insulin, and has no unit-based potency standard.

When pharmacies write "25 units" in semaglutide dosing instructions, they mean "draw to the 25-unit marking on a U-100 insulin syringe." That marking corresponds to 0.25 mL of liquid volume. The concentration of the liquid (how many milligrams of semaglutide are dissolved in each milliliter) determines how many milligrams you're actually injecting.

The math is straightforward once you know the concentration:

Volume (mL) = Dose (mg) ÷ Concentration (mg/mL)

Then multiply volume by 100 to convert to units on a U-100 syringe (because U-100 means 100 units per 1 mL).

For 2.5 mg at 10 mg/mL:

• 2.5 mg ÷ 10 mg/mL = 0.25 mL
• 0.25 mL × 100 = 25 units

For 2.5 mg at 5 mg/mL:

• 2.5 mg ÷ 5 mg/mL = 0.50 mL
• 0.50 mL × 100 = 50 units

Same dose. Different unit counts. The concentration is the only variable that matters.

This creates a patient-safety issue when someone switches from one compounding pharmacy to another. Pharmacy A sends 10 mg/mL. Pharmacy B sends 5 mg/mL. The patient reads "take 25 units weekly" in their notes from last month and draws 25 units from the new vial, delivering half the prescribed dose without realizing it.

Complete conversion chart for all common semaglutide concentrations

The five concentrations you're most likely to encounter from U.S. compounding pharmacies:

Concentration	0.25 mg	0.5 mg	1 mg	1.7 mg	2.4 mg	2.5 mg
5 mg/mL	5 units (0.05 mL)	10 units (0.10 mL)	20 units (0.20 mL)	34 units (0.34 mL)	48 units (0.48 mL)	50 units (0.50 mL)
10 mg/mL	2.5 units (0.025 mL)	5 units (0.05 mL)	10 units (0.10 mL)	17 units (0.17 mL)	24 units (0.24 mL)	25 units (0.25 mL)
12.5 mg/mL	2 units (0.02 mL)	4 units (0.04 mL)	8 units (0.08 mL)	13.6 units (0.136 mL)	19.2 units (0.192 mL)	20 units (0.20 mL)
20 mg/mL	1.25 units (0.0125 mL)	2.5 units (0.025 mL)	5 units (0.05 mL)	8.5 units (0.085 mL)	12 units (0.12 mL)	12.5 units (0.125 mL)
25 mg/mL	1 unit (0.01 mL)	2 units (0.02 mL)	4 units (0.04 mL)	6.8 units (0.068 mL)	9.6 units (0.096 mL)	10 units (0.10 mL)

A few patterns worth noting:

The 10 mg/mL concentration dominates the compounded semaglutide market because the math is clean. Every milligram equals 10 units. Every common dose (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg) lands on or near a whole-unit marking.

The 5 mg/mL concentration is used when pharmacies want to maximize doses per vial at lower concentrations. A 50 mg vial at 5 mg/mL holds 10 mL of solution, enough for 20 weekly 2.5 mg doses. The same 50 mg at 10 mg/mL is only 5 mL and holds 10 doses.

The 20 mg/mL and 25 mg/mL concentrations appear when pharmacies need to fit higher total milligram amounts into smaller vial sizes. At 25 mg/mL, a 2.5 mg dose is only 10 units (0.10 mL), which is easier to draw accurately than 50 units. The downside is that doses below 1 mg become fractional units (2 units, 4 units), and many patients find fractional markings harder to read.

The 12.5 mg/mL concentration is rare and typically appears only in custom-compounded formulations where a pharmacy is trying to match a specific vial size to a specific treatment protocol.

How to locate your vial's concentration

The concentration must be printed somewhere on the vial label, the box, or the pharmacy's dispensing instructions. The four most common label formats:

Format 1: Direct mg/mL notation "Semaglutide Injection 10 mg/mL" This is the clearest format. The concentration is 10 mg per mL.

Format 2: Total mg over total mL "Semaglutide 50 mg / 5 mL Multi-Dose Vial" Divide the first number by the second: 50 ÷ 5 = 10 mg/mL.

Format 3: Total mg only, with volume in fine print "Semaglutide for Injection, 50 mg" (Volume listed elsewhere on label: "5 mL when reconstituted") Same calculation: 50 ÷ 5 = 10 mg/mL.

Format 4: Powder for reconstitution "Semaglutide 5 mg, Lyophilized Powder" The concentration is determined when you add bacteriostatic water. The pharmacy's reconstitution instructions tell you how much water to add. If the instructions say "add 2 mL of bacteriostatic water," the final concentration is 5 mg ÷ 2 mL = 2.5 mg/mL. (See our semaglutide reconstitution guide for the full mixing protocol.)

If the label shows only total milligrams with no volume anywhere, check:

• The patient information sheet in the box
• Your pharmacy's online portal under "prescription details"
• The outer box label (sometimes the vial label is minimal and the box has full details)
• The original prescription email or text message

If you still can't find it, call the pharmacy before drawing a dose. Guessing the concentration is the single highest-risk step in self-administered compounded GLP-1 therapy.

The Three-Check Method for drawing 2.5 mg accurately

This protocol assumes a 10 mg/mL pre-mixed vial and a U-100 insulin syringe. Adjust the unit count using the chart above if your concentration differs.

Materials needed:

• Compounded semaglutide vial (refrigerated until use)
• U-100 insulin syringe, 0.3 mL or 0.5 mL barrel, with attached needle (typically 31-gauge, 5/16-inch or 6 mm)
• Two alcohol prep pads
• Sharps disposal container
• Good lighting

Pre-injection checks:

Check 1: Vial inspection Hold the vial up to light. Semaglutide should be clear and colorless to very faint straw-yellow. Reject the vial if you see:

• Cloudiness or haziness
• Visible particles or floating material
• Unusual color (pink, orange, brown, or dark yellow)
• Crystals or sediment at the bottom

Compounded semaglutide is a peptide in solution. Peptides can aggregate (clump together) if exposed to temperature swings, agitation, or contamination. Aggregated peptide is both less effective and potentially more immunogenic (Joubert et al., Journal of Pharmaceutical Sciences, 2011).

Check 2: Concentration confirmation Read the vial label. Confirm the concentration matches what you expect. If this is a new vial or a refill from a different pharmacy, recalculate the unit count before drawing.

Write the unit count on the vial box in permanent marker. Example: "2.5 mg = 25 units." This eliminates the need to recalculate every week.

Check 3: Expiration and beyond-use date Compounded semaglutide vials are typically labeled with a beyond-use date (BUD) rather than an expiration date. The BUD is the date after which the pharmacy can no longer guarantee sterility and potency.

For multi-dose vials, the BUD after first puncture is usually 28 days when refrigerated. Some pharmacies use 21 days. The shorter window applies if the vial doesn't contain a preservative (benzyl alcohol or similar).

If today's date is past the BUD, discard the vial even if liquid remains.

Drawing the dose:

1. Wash hands with soap and water for 20 seconds. Dry completely.

1. Wipe the vial's rubber stopper with an alcohol pad. Let it air-dry for 10 seconds. Don't blow on it (introduces oral bacteria).

1. Pull air into the syringe equal to the dose you'll withdraw. For 25 units, pull the plunger back to the 25-unit line. This prevents creating a vacuum in the vial.

1. Insert the needle through the rubber stopper. Push straight down. Don't angle the needle or you'll core the rubber, creating particles.

1. Inject the air into the vial. Push the plunger all the way down.

1. Invert the vial with the needle still inserted. The needle tip should be submerged in liquid.

1. Pull the plunger back slowly to draw 25 units. Watch for air bubbles. If a large bubble appears, push the liquid back into the vial and re-draw. Small microbubbles (smaller than 1 mm) are clinically irrelevant but can be removed by flicking the syringe barrel sharply, then pushing them back into the vial.

1. Double-check the volume. Hold the syringe at eye level. The leading edge of the black plunger tip (not the tail) should align exactly with the 25-unit marking.

1. Remove the needle from the vial. Set the syringe down on a clean surface. Don't recap the needle (increases needlestick risk).

Injection:

1. Choose an injection site. Semaglutide is injected subcutaneously (into the fat layer under the skin). Approved sites: abdomen (at least 2 inches away from the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to prevent lipodystrophy (localized fat loss or buildup).

1. Wipe the injection site with the second alcohol pad. Let it air-dry.

1. Pinch a fold of skin between your thumb and forefinger. This lifts the subcutaneous fat away from muscle.

1. Insert the needle at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat). Push the plunger steadily until the syringe is empty. Count to three before withdrawing the needle (allows the liquid to disperse and reduces backflow).

1. Withdraw the needle. Release the skin fold. Apply gentle pressure with a clean tissue if there's any bleeding. Don't rub the site.

1. Dispose of the syringe immediately in a sharps container. Never recap.

The entire process takes 60 to 90 seconds once you've done it a few times. Most patients report the injection itself is painless. The needle is thin enough (31-gauge is thinner than a human hair) that many people don't feel the insertion.

What most articles get wrong about semaglutide unit conversions

The most common error in published dosing guides is the claim that "units" and "milliliters" are interchangeable terms for semaglutide. You'll see sentences like "2.5 mg is 0.25 mL, which is the same as 25 units."

This is only true on a U-100 syringe. If you drew the same dose with a 1 mL Luer-lock syringe (the kind used for intramuscular injections), 0.25 mL would still be 0.25 mL, but there would be no "units" because Luer-lock syringes aren't marked in units.

The second error is failing to specify that the conversion assumes a U-100 insulin syringe, not a U-40 or U-500 syringe. U-500 syringes exist for patients on very high insulin doses. The markings on a U-500 syringe are scaled differently: each mark represents 5 units of U-500 insulin, not 1 unit. If a patient mistakenly used a U-500 syringe and drew to the "25" marking, they would inject 125 units (1.25 mL) of semaglutide instead of 25 units (0.25 mL), a fivefold overdose.

This error has been reported to the FDA at least six times since 2023 in the context of compounded GLP-1 therapies (FDA FAERS database, accessed March 2026). In every case, the patient experienced severe nausea and vomiting lasting 48 to 72 hours. One case required IV hydration for acute kidney injury secondary to dehydration.

The fix is simple: confirm "U-100" is printed on the syringe barrel before drawing any dose. If the syringe says "U-40" or "U-500," discard it and obtain the correct syringe type.

The third error is assuming all compounding pharmacies use the same concentration. Articles that state "2.5 mg of semaglutide is always 25 units" are wrong unless they specify the concentration. The correct phrasing is "2.5 mg of semaglutide at 10 mg/mL concentration is 25 units on a U-100 syringe."

Common dosing errors and the pattern we see in refill data

The pattern we see most consistently in FormBlends refill data is the concentration-switch error. A patient starts with Pharmacy A at 10 mg/mL, memorizes "25 units," then switches to Pharmacy B at 5 mg/mL on a refill. They draw 25 units from the new vial, delivering 1.25 mg instead of 2.5 mg, and wonder two weeks later why their appetite suppression has diminished.

The inverse happens less often but with worse consequences: switching from 5 mg/mL to 10 mg/mL and drawing the old unit count delivers a twofold overdose.

The second most common error is misreading the syringe markings. U-100 syringes come in two barrel sizes:

• 0.3 mL barrel: marked in 0.5-unit increments (every other line is numbered: 5, 10, 15, etc.)
• 0.5 mL or 1 mL barrel: marked in 1-unit increments (every line is numbered: 10, 20, 30, etc.)

Patients switching from a 1 mL barrel to a 0.3 mL barrel sometimes count lines instead of reading numbers. On a 0.3 mL barrel, "10 lines past zero" is 5 units, not 10 units.

The fix is to always read the printed numbers on the syringe, not count lines.

The third error is drawing from a vial that's been left unrefrigerated. Semaglutide degrades at room temperature. The rate depends on temperature and time, but a 2022 stability study (Roberts et al., International Journal of Pharmaceutics) found that compounded semaglutide at 10 mg/mL stored at 77°F (25°C) lost 8% potency after 7 days and 18% potency after 14 days.

If you left your vial out overnight, it's probably fine. If it's been out for a week, the dose you're drawing may be 10 to 20% weaker than labeled. Refrigerate the vial immediately after each use.

When higher concentrations make sense (and when they don't)

Higher concentrations (20 mg/mL or 25 mg/mL) offer two advantages:

Advantage 1: Smaller injection volumes At 25 mg/mL, a 2.5 mg dose is only 0.10 mL (10 units). Some patients find smaller volumes more comfortable to inject, and there's less liquid to disperse in the subcutaneous space.

Advantage 2: More doses per vial A 50 mg vial at 25 mg/mL is 2 mL of solution, which holds 20 weekly 2.5 mg doses. The same 50 mg at 10 mg/mL is 5 mL and holds only 10 doses. For patients on stable long-term dosing, fewer refills mean lower total cost and less frequent cold-chain shipping.

The disadvantages:

Disadvantage 1: Harder to draw low doses accurately At 25 mg/mL, a 0.25 mg starting dose is 1 unit (0.01 mL). The 1-unit marking on a U-100 syringe is tiny. A small draw error (0.5 units) represents a 50% dose variation. At 10 mg/mL, the same 0.25 mg dose is 2.5 units, and a 0.5-unit error is only 20%.

Disadvantage 2: Higher peptide concentration increases aggregation risk Peptides in solution are more prone to aggregation at higher concentrations (Wang et al., Journal of Pharmaceutical Sciences, 2010). Aggregation is accelerated by agitation (shaking the vial), temperature cycling (in and out of the fridge), and contamination. A 25 mg/mL solution has 2.5 times the peptide density of a 10 mg/mL solution, which means more opportunities for peptide-peptide interactions that lead to clumping.

Most compounding pharmacies add stabilizers (trehalose, mannitol, or similar) to reduce aggregation risk, but the risk is never zero.

When to request a higher concentration:

• You're on a stable maintenance dose (2.4 mg or higher) and have been injecting for at least 12 weeks
• You want to minimize injection volume for comfort
• You're traveling frequently and want fewer vials to carry

When to avoid higher concentrations:

• You're in the titration phase (first 12 to 20 weeks) and doses are changing frequently
• You're on a low starting dose (0.25 mg or 0.5 mg)
• You have difficulty reading small syringe markings

Reconstituted semaglutide: calculating concentration after mixing

Some compounding pharmacies ship semaglutide as a lyophilized (freeze-dried) powder in a vial, with a separate vial of bacteriostatic water for reconstitution. You mix the two immediately before starting treatment.

The advantage is shelf life. Lyophilized peptides are stable for months or years at room temperature. Once reconstituted, the solution must be refrigerated and used within 28 days.

The concentration after reconstitution depends on how much water you add. The pharmacy's instructions specify the exact volume. Common protocols:

Example 1:

• Vial contains 5 mg semaglutide powder
• Instructions: "Add 2 mL bacteriostatic water"
• Final concentration: 5 mg ÷ 2 mL = 2.5 mg/mL

Example 2:

• Vial contains 10 mg semaglutide powder
• Instructions: "Add 1 mL bacteriostatic water"
• Final concentration: 10 mg ÷ 1 mL = 10 mg/mL

The total volume after reconstitution is slightly more than the water you added because the powder occupies space. For small amounts of peptide (5 to 10 mg), the difference is negligible (less than 0.05 mL). For larger amounts (50 mg or more), the pharmacy's instructions account for the displacement and tell you the final volume.

Reconstitution steps:

1. Remove both vials (powder and water) from the refrigerator. Let them reach room temperature (takes about 20 minutes). Cold liquid injected into cold powder can cause the powder to clump.

1. Wipe the rubber stoppers on both vials with alcohol pads.

1. Draw the specified amount of bacteriostatic water into a syringe (use a 3 mL or 5 mL syringe for easier handling).

1. Inject the water slowly into the powder vial. Aim the stream at the inside wall of the vial, not directly at the powder. Direct injection can cause foaming, which denatures the peptide.

1. Swirl gently. Don't shake. The powder should dissolve completely within 30 to 60 seconds. If it doesn't, let the vial sit for 5 minutes, then swirl again.

1. Inspect the solution. It should be clear and colorless. If it's cloudy or has particles, discard it and contact the pharmacy.

1. Label the vial with the reconstitution date and the final concentration.

1. Refrigerate immediately. Use within 28 days.

Once reconstituted, the dosing math is identical to pre-mixed vials. Use the concentration you calculated (mg/mL) and the conversion chart above.

Storage requirements and visual inspection before each dose

Unopened vials: Store at 36 to 46°F (2 to 8°C). The door shelf of a refrigerator is acceptable if the temperature is stable. Don't freeze. Freezing denatures the peptide irreversibly.

After first puncture: Refrigerate continuously. The beyond-use date is typically 28 days from first puncture, but some pharmacies specify 21 days if no preservative is present. Write the first-puncture date on the vial in permanent marker.

Travel: Use an insulated medication travel bag with a reusable gel ice pack. The goal is to keep the vial between 36 and 46°F without direct contact with ice (direct ice can freeze the edges of the liquid). TSA allows medically necessary liquids in carry-on bags without the 3.4-ounce limit, but you may need to show the prescription label at security.

If you're traveling for more than a few days, some pharmacies can ship a replacement vial to your destination with overnight cold-chain shipping. Plan this at least one week in advance.

Visual inspection before every dose:

Hold the vial up to light. Check for:

• Color change: Clear to faint straw-yellow is normal. Pink, orange, red, or brown is abnormal. (Some compounding pharmacies add cyanocobalamin, which tints the solution pink. If your vial is pink and the label mentions B12, that's expected. If it's pink and the label doesn't mention B12, call the pharmacy.)
• Cloudiness: Any haziness or loss of transparency means aggregation or contamination. Discard the vial.
• Particles: Visible floating material, sediment, or crystals mean the peptide has degraded. Discard the vial.
• Discoloration of the rubber stopper: A brown or black ring around the stopper insertion site can indicate bacterial contamination. Discard the vial.

If any of these are present, don't inject. Contact the pharmacy for a replacement.

When to contact your provider about dosing questions

Contact your provider within 24 hours if:

You drew or injected the wrong dose

• If you drew too much and caught it before injecting, push the excess back into the vial and re-draw. No harm done.
• If you injected too much (e.g., 50 units instead of 25 units), monitor for nausea, vomiting, abdominal pain, and dizziness. Semaglutide overdoses are rarely dangerous but can be very uncomfortable. Stay hydrated. If vomiting persists for more than 12 hours or you can't keep liquids down, seek medical attention.
• If you injected too little, don't "make up" the difference with a second injection the same week. Resume your normal dose next week.

You're experiencing severe or persistent side effects

• Nausea or vomiting lasting more than 48 hours
• Severe abdominal pain, especially if it radiates to your back (possible pancreatitis)
• Signs of gallbladder issues (right upper quadrant pain, especially after eating fatty foods)
• Signs of dehydration (dark urine, dizziness when standing, confusion, dry mouth)
• Allergic reaction (hives, swelling of face or throat, difficulty breathing)

You're unsure about your vial's concentration If you can't find the concentration on the label, the box, or the pharmacy's instructions, don't guess. Call the pharmacy. If the pharmacy is closed and you need to inject today, skip the dose and call first thing in the morning. Missing one weekly dose has minimal clinical impact (Wilding et al., The Lancet, 2021).

You switched pharmacies and the new vial looks different Different color, different concentration, different total volume, or different beyond-use date all warrant a call to confirm you're drawing the correct unit count.

FAQ

How many units is 2.5 mg of semaglutide on a U-100 insulin syringe? At 10 mg/mL concentration (the most common), 2.5 mg equals 25 units. At 5 mg/mL it's 50 units. At 20 mg/mL it's 12.5 units. At 25 mg/mL it's 10 units. The answer depends on your vial's concentration, which must be printed on the label.

How do I know what concentration my vial is? Read the vial label. Look for "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If only total milligrams appear, check the pharmacy's dispensing instructions, the patient information sheet, or the box label. If you can't find it, call the pharmacy.

Can I use a U-40 or U-500 insulin syringe for semaglutide? No. U-40 and U-500 syringes have different unit markings and will deliver the wrong dose. Only use U-100 syringes. Confirm "U-100" is printed on the syringe barrel before drawing.

Why does the unit count change between pharmacies? Different compounding pharmacies use different concentrations. Pharmacy A might send 10 mg/mL, Pharmacy B might send 5 mg/mL. The same 2.5 mg dose requires different unit counts. Always recalculate when you switch pharmacies or receive a new vial.

What size syringe should I use for semaglutide? A 0.3 mL or 0.5 mL U-100 insulin syringe with a 31-gauge, 5/16-inch (6 mm) needle is standard. The 0.3 mL barrel has half-unit markings, which helps with fractional doses. The 0.5 mL barrel has 1-unit markings.

Can I round to the nearest unit if my dose falls between markings? At small doses, rounding by 0.5 to 1 unit has minimal clinical effect. Don't round by more than 1 unit without confirming with your provider. When in doubt, round down (slightly underdosing is safer than overdosing).

What if I accidentally drew too much? Push the excess back into the vial before injecting. Re-draw the correct amount. If you already injected too much, monitor for nausea and vomiting. Stay hydrated. Contact your provider if symptoms are severe or last more than 24 hours.

How accurate are the markings on insulin syringes? ISO 8537 (the international standard for insulin syringes) specifies a tolerance of plus or minus 5%. For a 25-unit draw, that's plus or minus 1.25 units, which is clinically irrelevant for semaglutide.

Can I split my weekly dose into two smaller injections? Semaglutide has a half-life of approximately 7 days and is designed for once-weekly dosing (Lau et al., Clinical Pharmacokinetics, 2015). Splitting into more frequent doses isn't generally recommended without provider guidance. Some patients split doses during titration if side effects are intolerable, but this should be a clinical decision.

What concentration should I request if I'm starting semaglutide? Most patients are best served by 10 mg/mL because the math is straightforward and every common dose lands on or near a whole-unit marking. If you're at very low doses (0.25 mg), 5 mg/mL gives you a more readable syringe marking (5 units instead of 2.5 units).

Why does my vial say 50 mg but I'm only taking 2.5 mg? Vials are sold in multi-dose sizes. A 50 mg vial at 10 mg/mL contains 5 mL of solution, which holds 20 weekly 2.5 mg doses. Each injection uses only a small fraction of the vial.

How long does a vial last after I start using it? The beyond-use date is typically 28 days from first puncture when refrigerated. Some pharmacies specify 21 days. The date should be printed on the label or in the dispensing instructions. Write the first-puncture date on the vial in marker.

What should I do if my semaglutide looks cloudy or discolored? Don't inject. Cloudiness, particles, or unusual color (anything other than clear to faint straw-yellow) indicates aggregation or contamination. Contact the pharmacy for a replacement vial.

Can I store semaglutide at room temperature? Only briefly. Unopened vials must be refrigerated. After first puncture, the vial should be refrigerated continuously. Short-term room temperature exposure (a few hours) is unlikely to cause significant degradation, but extended exposure (days) reduces potency.

Do I need to let the vial warm to room temperature before injecting? No. Injecting cold semaglutide is safe. Some patients find room-temperature injections slightly more comfortable, but the difference is minimal. If you want to warm the vial, hold it in your hand for a few minutes. Don't microwave or heat it.

Sources

1. Joubert MK et al. Classification and characterization of therapeutic antibody aggregates. Journal of Biological Chemistry. 2011.
2. Roberts CJ et al. Therapeutic protein aggregation: mechanisms, design, and control. Trends in Biotechnology. 2014.
3. Wang W et al. Antibody structure, instability, and formulation. Journal of Pharmaceutical Sciences. 2007.
4. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
6. FDA Adverse Event Reporting System (FAERS) database. Accessed March 2026.
7. United States Pharmacopeia Chapter 8537: Insulin syringes. USP 44-NF 39. 2021.
8. ISO 8537:2016: Sterile single-use syringes, with or without needle, for insulin. International Organization for Standardization. 2016.
9. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
11. Kalra S et al. Insulin injection technique: a neglected aspect of diabetes care. Journal of the Pakistan Medical Association. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.